


Cost-Effectiveness Analysis of Amputation Risk and Cardiovascular (CV) Benefits with Canagliflozin in Patients with Type II Diabetes Mellitus

Hoang, Celia; Ahmadyar, Gina; Tinoco, Elizabeth; Wilson,
Leslie, Ph.D; Weng, Xiuhua, Ph.D.



Background



Canagliflozin Indications

- Pharmacological management of type 2 diabetes mellitus (T2DM)
- Risk reduction of end-stage renal disease (ESRD)
- **Risk reduction of major cardiovascular events in adults with type 2 diabetes (T2DM) and established cardiovascular disease**

2. Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2013

3. Bommel EJM van, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, Raalte DH van. SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome. *CJASN*. 2017;12(4):700-710.

doi:10.2215/CJN.06080616

ORIGINAL ARTICLE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, M.B., Ch.B., Ph.D., Vlado Perkovic, M.B., B.S., Ph.D.,
Kenneth W. Mahaffey, M.D., Dick de Zeeuw, M.D., Ph.D., Greg Fulcher, M.D.

CONCLUSIONS

In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal. (Funded by Janssen Research and Development; CANVAS and CANVAS-R ClinicalTrials.gov numbers, NCT01032629 and NCT01989754, respectively.)

Key outcomes.

METHODS

The CANVAS Program integrated data from two trials involving a total of 30,342 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

Objective

To evaluate the cost-effectiveness of canagliflozin plus background therapy considering both amputations risk and cardiovascular (CV) benefits compared to background therapy alone



Methods



	Base-Case Model	Maximum Benefit Model
Number of Health States	6	6
Perspective	Payer	Payer
Time-Horizon	84 months	84 months
Willingness-to-Pay Threshold (WTP)	\$100,000	\$100,000
Costs	Events: average cost Canagliflozin: WAC	Events: first-year costs Canagliflozin: half of WAC
Utilities	Standard Value	Half Standard Value

Methods



TABLE 1: Utility and Cost Inputs				
	Base Case Model		Maximum Benefit Model	
Event Measured	Utility Value	Costs ³	Utility Value	Costs ³
Month-Supply of Canagliflozin	---	\$518 ¹⁰	---	\$259 ¹⁰
Month-Supply of Baseline Medications	---	\$381.52 ¹¹	---	\$381.52 ¹¹
Cardiac				
Nonfatal MI or Stroke (Canagliflozin)	0.68 ⁵	\$1295.07 ¹²	0.34 ⁵	\$4755.57 ¹²
Nonfatal MI or Stroke (Placebo)	0.69 ⁵	\$1276.22 ¹²	0.345 ⁵	\$4783.61 ¹²
Amputations				
Amputation (Canagliflozin)	0.56 ⁵	\$291.87 ¹³	0.28 ⁵	\$1898.81 ¹³
Amputation (Placebo)		\$386.04 ¹³		\$1836.57 ¹³
Amputation + Nonfatal MI or Stroke(Canagliflozin)	0.48 ⁵	\$1689.99 ^{12,13}	0.24 ⁵	\$6654.38 ^{12,13}
Amputation + Nonfatal MI or Stroke(Placebo)	0.49 ⁵	\$1397.90 ^{12,13}	0.245 ⁵	\$5635.36 ^{12,13}
Adverse Events (AE)**				
Total AE for Canagliflozin	0.75 ⁶⁻⁸	\$140.89 ^{12,14}	0.75 ⁶⁻⁸	\$140.89 ^{12,14}
Total AE for Placebo	0.79 ⁶⁻⁸	\$76.89 ^{12,14}	0.79 ⁶⁻⁸	\$76.89 ^{12,14}
Death				
CV-Related	0	\$21021.73 ¹⁵	0	\$21021.73 ¹⁵
Non CV-Related	0	\$22475.64 ¹⁶	0	\$22475.64 ¹⁶

*AE: UTI, vulvovaginal candidiasis, osmotic diuresis, and volume depletion

Event was defined as nonfatal myocardial infarction (MI) or stroke, amputation, or both amputation and nonfatal MI/stroke.

5. Consumer Price Index for Medical Care Services. US Department of Labor, Bureau of Labor Statistics, 2006. <http://www.bls.gov/cpi>. Accessed June 1, 2020.

6. Lung TWC, Hayes AJ, Hayen A, Farmer A, Clarke PM. A meta-analysis of health state valuations for people with diabetes: exploring the variation across methods and implications for economic evaluation. *Qual Life Res*. 2011;20(10):1669-1678. doi:10.1007/s11136-011-9909-z

7. Shingler S, Fordham B, Evans M, et al. Utilities for treatment-related adverse events in type 2 diabetes. *Journal of Medical Economics*. 2015;18(1):45-55. doi:10.3111/jme.2014.021159

8. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. *BJU Int*. 2008;101(11):1388-1395. doi:10.1111/j.1464-410X.2008.07261.x

9. Neillson C, Tschannbauer A, Johansen P, Wills M, Valencia-Mendoza A, Pflug A, O'D. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. *Value in Health Regional Issues*. 2015;6:6-19. doi:10.1016/j.vhri.2015.01.002

10. Canagliflozin (2020). Redbook ®. Retrieved on May 15, 2020. <https://micromedex.com>. Greenwood Village, CO: Thompson Monomedex.

11. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. *Diabetes Care*. 2018;41(5):917-928. doi:10.2337/dci18-0007

12. Ward A, Alvarez P, Yo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). *Journal of Medical Economics*. 2014;17(3):176-183. doi:10.3111/13669698.2014.882643

13. HCUP National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), 2012. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/nisoverview.jsp

14. CMS. Physician Fee Schedule - National Payment Amount File. Baltimore, MD: Centers for Medicare & Medicaid Services (CMS), 2020. Available at: <https://www.cms.gov/apps/physician-fee-schedules/search/search-criteria.aspx>. Accessed June 1, 2020

15. Shetty S, Staffey-Malley D, Yue B, et al. The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. *Current Medical Research and Opinion*. 2018;34(6):1061-1067. doi:10.1080/03007995.2018.1444500

16. Zhuo X, Zhang P, Hoerger TJ. Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications. *American Journal of Preventive Medicine*. 2013;45(3):253-261. doi:10.1016/j.amepre.2013.04.017

Results – Base Case Model



TABLE 2: Base Case Model - Incremental Cost, Incremental Effectiveness, and ICER/QALYs					
	Cost (2020 USD)	Incremental Cost (2020 USD)	Effectiveness (QALY)	Incremental Effectiveness (QALY)	ICER
BT alone	\$39,737.69	N/A	5.01	N/A	N/A
CANA + BT	\$81,022.30	\$41,284.61	5.04	0.03	\$1,294,370

TABLE 3: Base Case Model - Sensitivity Analyses on Amputation and CV Events in the Canagliflozin Group			
Variable	Reference Values	Range	Results
Probability of Nonfatal MI/Stroke	0.001227786	0 - 0.001534732	ICER > \$100,00 WTP threshold
Probability of Amputation	0.000525	0 - 0.00065625	ICER > \$100,00 WTP threshold

Results – Maximum Benefit Model



TABLE 4: Maximum Benefit Model - Incremental Cost, Incremental Effectiveness, and ICER/QALYs					
	Cost (2020 USD)	Incremental Cost (2020 USD)	Effectiveness (QALY)	Incremental Effectiveness (QALY)	ICER
BT alone	\$57,764.44	N/A	4.86	N/A	\$524,220
CANA + BT	\$76,838.18	\$19,073.74	4.90	0.036	

TABLE 5: Maximum Benefit Model - Sensitivity Analyses on Amputation, CV Events, Costs of Canagliflozin in the Canagliflozin Group			
Variable	Reference Values	Range	Results
Probability of Nonfatal MI/Stroke	0.00093694	0 - < 0.000029	Cana dominant
		0.000029 - 0.00064	Cana more CE
		> 0.00064	ICER > \$100,00 WTP threshold
Probability of Amputation	0.000525	0 - 0.00065625	ICER > \$100,00 WTP threshold
Cost of Canagliflozin	\$259	0 - 20.23	Cana dominant
		>20.23 - 64.75	Cana more CE
		> 64.75	ICER > \$100,00 WTP threshold

Discussion/Conclusion

- CV benefits awarded by canagliflozin did not translate to canagliflozin being cost-effective in the base case scenario or in the maximum benefit scenario
- Canagliflozin drug cost was a strong driver of cost-effectiveness in our models
- The models were not sensitive to the trade-offs in probability of amputation and CV risk
- Canagliflozin may still provide benefit to certain individuals with T2DM



Questions?



	Email
Celia Hoang	celia.hoang@ucsf.edu
Gina Ahmadyar	gina.ahmadyar@ucsf.edu
Elizabeth Tinoco	elizabeth.tinoco@ucsf.edu

References



1. GoodRx List Price Index Reveals Rising Cost of Diabetes Treatments - GoodRx. The GoodRx Prescription Savings Blog. Published April 10, 2019. Accessed October 8, 2020. <https://www.goodrx.com/blog/goodrx-list-price-index-rising-cost-of-diabetes-treatments/>
2. Invokana [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2013
3. Bommel EJM van, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, Raalte DH van. SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome. *CJASN*. 2017;12(4):700-710. doi:10.2215/CJN.06080616
4. Neal B, Perkovic V, Mahaffey KW, et al. (CANVAS Program) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *New England Journal of Medicine*. 2017;377(7):644-657. doi:[10.1056/NEJMoa1611925](https://doi.org/10.1056/NEJMoa1611925)
5. Consumer Price Index for Medical Care Services. US Department of Labor, Bureau of Labor Statistics, 2006. <http://www.bls.gov/cpi>. Accessed June 1, 2020.
6. Lung TWC, Hayes AJ, Hayen A, Farmer A, Clarke PM. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. *Qual Life Res*. 2011;20(10):1669-1678. doi:[10.1007/s11136-011-9902-y](https://doi.org/10.1007/s11136-011-9902-y)
7. Shingler S, Fordham B, Evans M, et al. Utilities for treatment-related adverse events in type 2 diabetes. *Journal of Medical Economics*. 2015;18(1):45-55. doi:[10.3111/13696998.2014.971158](https://doi.org/10.3111/13696998.2014.971158)
8. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. *BJU Int*. 2008;101(11):1388-1395. doi:[10.1111/j.1464-410X.2008.07601](https://doi.org/10.1111/j.1464-410X.2008.07601).
9. Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A, Puig A. OD: Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. *Value in Health Regional Issues*. 2015;8:8-19. doi:10.1016/j.vhri.2015.01.002
10. Canagliflozin (2020). Redbook ®. Retrieved on May 15, 2020. <https://micromedexsolutions.com>. Greenwood Village, CO. Thompson Micromedex.
11. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. *Dia Care*. 2018;41(5):917-928. doi:10.2337/dci18-0007
12. Ward A, Alvarez P, Vo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). *Journal of Medical Economics*. 2014;17(3):176-183. doi:10.3111/13696998.2014.882843
13. HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2012. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/nisoverview.jsp
14. CMS. Physician Fee Schedule – National Payment Amount File. Baltimore, MD: Centers for Medicare & Medicaid Services (CMS), 2020. Available at: <https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx>. Accessed June 1, 2020]
15. Shetty S, Stafkey-Mailey D, Yue B, et al. The cost of cardiovascular-disease-related death in patients with type 2 diabetes mellitus. *Current Medical Research and Opinion*. 2018;34(6):1081-1087. doi:10.1080/03007995.2018.1445620
16. Zhuo X, Zhang P, Hoerger TJ. Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications. *American Journal of Preventive Medicine*. 2013;45(3):253-261. doi:10.1016/j.amepre.2013.04.017